Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Goldentree Asset Management LP bought 150,652 shares of Keenova Therapeutics plc at $89.25 to $91.00 a share (average $90.65) in 2 transactions, worth $13.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 9,026,195 (+1.4%).
Consensus Cloud Solutions Director Nathaniel Simmons Sells $342K of Stock
Nathaniel Simmons, Director, sold 8,000 shares of Consensus Cloud Solutions, Inc. at $42.46 to $42.90 a share (average $42.78) in 2 transactions, worth $342K in total on Nov 9, 2026. Shares held after the trade: 23,658 (-19.6%).
LEE ENTERPRISES Director David Henry Hoffmann Buys $99.3K of Stock
David Henry Hoffmann, Director, bought 14,056 shares of LEE ENTERPRISES, Inc at $6.96 to $7.17 a share (average $7.07) in 2 transactions, worth $99.3K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 11,544,637 (+0.1%).
Claritev Insider Ares Management LLC Buys $2.94M of Stock
Ares Management LLC bought 115,579 shares of Claritev Corp at $24.42 to $26.14 a share (average $25.40) in 2 transactions, worth $2.94M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,049,518 (+3.3%).
Intercontinental Exchange General Counsel Andrew J. Surdykowski Sells $801K of Stock
Andrew J. Surdykowski, General Counsel, sold 4,575 shares of Intercontinental Exchange, Inc. at $174.04 to $176.22 a share (average $175.05) in 3 transactions, worth $801K in total on Nov 10, 2026. Shares held after the trade: 40,554 (-1.4%).
CareDx Secretary and General Counsel Jeffrey Adam Novack Sells $332K of Stock
Jeffrey Adam Novack, Secretary and General Counsel, sold 4,096 shares of CareDx, Inc. at $80.47 to $83.33 a share (average $81.13) in 3 transactions, worth $332K in total on Nov 10, 2026. Shares held after the trade: 96,604 (-0.9%).
Audax Private Credit Fund, LLC reported a net increase in net assets from operations of $25.6 million for the nine months ended September 30, 2026, compared to $15.2 million in the prior year period. Total investments at fair value grew to $1.21 billion, while the fund maintained a net asset value per share of $24.86.
KBS Real Estate Investment Trust III, Inc. reported a net loss of $137.1 million for the nine months ended September 30, 2026, compared to a $59.9 million loss in the prior year period. The increased loss was driven by $80.0 million in real estate impairment charges and a $19.2 million unrealized loss on real estate equity securities.
Solaris Energy Infrastructure Insider Aj Teague Buys $30.8K of Stock
Aj Teague bought 520 shares of Solaris Energy Infrastructure, Inc. at $59.23 to $59.50 a share (average $59.32) in 2 transactions, worth $30.8K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 117,385 (+0.1%).
Toast Insider Susan Chapman-Hughes Sells $235K of Stock
Susan Chapman-Hughes sold 6,885 shares of Toast, Inc. at $34.13 a share, worth $235K in total on Nov 11, 2026. Shares held after the trade: 7,645 (-47.4%).
Planet 13 Holdings reported Q3 2026 revenue of $23.1 million, a 1.0% sequential increase driven by strong growth in Florida. The company significantly reduced its net loss to $6.4 million compared to $44.0 million in the prior year, aided by improved gross margins and the exit from California operations. Management highlighted the upcoming December 10 shareholder vote on its proposed merger with Vireo Growth.
Term
Q3 2026
“Revenue increased for the second consecutive quarter, up 1.0% sequentially, led by a 15.1% quarter-over-quarter increase in Florida, where revenue was 45% higher than in the prior-year quarter. The levers we have been pulling in Florida are showing up in the numbers driven by better flower out of our upgraded cultivation, a fuller product lineup with BHO concentrates now on shelf, and a more productive store network.”
Larry Scheffler, Co-CEO of Planet 13
“We delivered a second consecutive quarter of revenue growth and Adjusted EBITDA improvement, and our focus remains on running the business well and executing a smooth path to closing for our stockholders, employees, patients and customers. With the Form S-4 declared effective on November 2, our stockholders will vote on the proposed merger with Vireo Growth at a special meeting on December 10, 2026.”
Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, a 57.9% increase year-over-year, and total revenue of $6.9 million. The company completed enrollment in its first Phase 3 pivotal trial for common warts and unlocked $27.5 million in non-dilutive growth capital by meeting credit facility milestones.
Term
Q3 2026
“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer
“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer
Meta Platforms Debt Financing Update with Citigroup Global Markets Limited
Meta Platforms, Inc. completed a multi-tranche offering of Senior Notes denominated in Euros across six different maturities ranging from 2031 to 2065. The offering includes €1.75B of 4.300% notes due 2031, €1.25B of 4.650% notes due 2033, €1.00B of 4.900% notes due 2035, €1.75B of 5.400% notes due 2038, €1.75B of 6.050% notes due 2044, and €1.50B of 6.400% notes due 2065. The notes were issued under a seventh supplemental indenture with U.S. Bank Trust Company as trustee.
Counterparty
Citigroup Global Markets Limited and Morgan Stanley & Co. International plc
Robinhood Ventures Fund II reported a net investment loss of $1.87 million for the six months ended September 30, 2026, with total assets growing significantly to $217.1 million following its IPO in August 2026. The fund's net asset value per share decreased from $24.72 to $23.21 during the period, primarily driven by organizational expenses and offering costs.
Tim VP, Risk & Compliance Claudio Creo Sells $18.9K of Stock
Claudio Creo, VP, Risk & Compliance, sold 5,000 shares of Tim S.A. at $3.77 a share, worth $18.9K in total on Nov 10, 2026. Shares held after the trade: 21,798 (+29.8%).
Rtw Investments LP, 10% Owner, bought 1,200,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $6M in total on Nov 9, 2026. Shares held after the trade: 10,756,063 (+12.6%).
Ondas Inc. reported a significant revenue increase to $301.4 million for the nine months ended September 30, 2026, compared to $20.6 million in the prior year, primarily driven by acquisition activity. Despite a quarterly net loss of $64.7 million, the company achieved a net income of $206.9 million for the nine-month period, largely due to $583.4 million in other income.
Candel Therapeutics entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market (ATM) equity facility. The agreement allows the company to sell up to $50 million of common stock from time to time, in addition to the $50 million previously sold under a prior 2025 agreement.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on bacteriophage-based therapies. As of November 6, 2026, the company had 37,192,632 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
For the nine months ended September 30, 2026, Xos, Inc. reported revenues of $21.5 million, a significant decrease from $40.8 million in the prior year period. The company incurred a net loss of $19.4 million for the first nine months of 2026, while its cash position decreased to $12.1 million as of September 30, 2026.
Newsmax Inc. reported a significant financial turnaround for the nine months ended September 30, 2026, achieving a net income of $15.9 million compared to a net loss of $96.5 million in the prior year period. This improvement was driven by a 27.6% increase in total revenues to $174.8 million and a substantial reduction in general and administrative expenses, which had been inflated in 2025 by one-time corporate matters.
For the nine months ended September 30, 2026, iAnthus reported net revenues of $107.2 million and a net loss of $41.9 million, compared to a net loss of $26.1 million in the prior year period. The company's balance sheet shows a significant shift in debt classification, with $208.7 million in long-term debt moving to current liabilities, contributing to a total shareholders' deficit of $143.5 million.
Caci International Insider Debora A. Plunkett Sells $152K of Stock
Debora A. Plunkett sold 235 shares of Caci International Inc at $646.31 a share, worth $152K in total on Nov 11, 2026. Shares held after the trade: 2,447 (-8.8%).
Nuveen Farmland REIT commenced operations in late 2026, completing its initial closing on September 1, 2026, with $34.7 million in proceeds and acquiring an initial portfolio of two assets. For the nine months ended September 30, 2026, the company reported a net loss of $607,000, primarily driven by general and administrative expenses as it established its investment platform.
Ionic Digital Inc. reported a significant shift in its business model, with digital infrastructure leasing revenue of $131.7 million for the nine months ended September 30, 2026, surpassing its cryptocurrency mining revenue. Despite a net loss of $30.9 million for the nine-month period, the company achieved a net income of $17.4 million in the third quarter, bolstered by a $73.2 million gain on the fair value of cryptocurrency assets.
Vivos Inc. reported a net loss of $2,746,628 for the nine months ended September 30, 2026, compared to a loss of $1,987,503 in the prior year period, driven largely by a $847,628 non-operating loss on share issuances. While revenues increased significantly to $101,368 from $43,627, the company continues to operate with a substantial accumulated deficit of over $91 million.
KALA BIO filed a Certificate of Amendment to effect a 1-for-30 reverse stock split of its common stock, effective November 13, 2026. The split will reduce the number of outstanding shares from approximately 19.3 million to approximately 644,659 to meet market requirements. Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on November 16, 2026.
Nektar Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $952.9 million and the initiation of Phase 3 registrational trials for rezpegaldesleukin in atopic dermatitis. The company reported a net loss of $55.7 million on revenue of $9.4 million, with R&D expenses increasing to support its late-stage clinical programs.
Term
Q3 2026
“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”
Howard Robin, President and Chief Executive Officer of Nektar
INNOVATE Corp. reported a significant turnaround for the third quarter of 2026, with net income attributable to common stockholders of $15.8 million compared to a net loss of $9.4 million in the prior year. Revenue grew to $495.5 million for the quarter, driven by operations and a $32.9 million gain on the sale of a controlling interest in a subsidiary.
Beneficient received a deficiency notice from Nasdaq on November 5, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has until May 4, 2027, to regain compliance by maintaining an MVLS of at least $35 million for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's Class A common stock (BENF) or warrants (BENFW).